Analysis of prognostic factors and pharmacodynamic parameters in relapsed indolent B-NHL and mantle cell lymphoma (MCL) treated with rituximab.

被引：0
|
作者：
Tobinai, K
Igarashi, T
Ogura, M
Kinoshita, T
Kobayashi, Y
Sasaki, Y
Morishima, Y
Uike, N
Taniwaki, M
Kano, Y
Kasai, M
Ohnishi, K
机构：
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4808
引用
下载
收藏
页码：249B / 249B
页数：1
相关论文
共 50 条
  • [41] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Yosuke Matsumoto
    Tsutomu Kobayashi
    Yuji Shimura
    Eri Kawata
    Hisao Nagoshi
    Muneo Ohshiro
    Mio Sugitani
    Kazuho Shimura
    Toshiki Iwai
    Shin-ichi Fuchida
    Mihoko Yoshida
    Miki Kiyota
    Shinsuke Mizutani
    Yoshiaki Chinen
    Tomoko Takimoto-Shimomura
    Mitsushige Nakao
    Hiroto Kaneko
    Hitoji Uchiyama
    Nobuhiko Uoshima
    Hikari Nishigaki
    Yutaka Kobayashi
    Shigeo Horiike
    Chihiro Shimazaki
    Masafumi Taniwaki
    Junya Kuroda
    International Journal of Hematology, 2019, 110 : 77 - 85
  • [42] Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study
    Matsumoto, Yosuke
    Kobayashi, Tsutomu
    Shimura, Yuji
    Kawata, Eri
    Nagoshi, Hisao
    Ohshiro, Muneo
    Sugitani, Mio
    Shimura, Kazuho
    Iwai, Toshiki
    Fuchida, Shin-ichi
    Yoshida, Mihoko
    Kiyota, Miki
    Mizutani, Shinsuke
    Chinen, Yoshiaki
    Takimoto-Shimomura, Tomoko
    Nakao, Mitsushige
    Kaneko, Hiroto
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Nishigaki, Hikari
    Kobayashi, Yutaka
    Horiike, Shigeo
    Shimazaki, Chihiro
    Taniwaki, Masafumi
    Kuroda, Junya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (01) : 77 - 85
  • [43] Phase I study of a novel humanized anti-CD20 antibody, BM-ca, in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Suzuki, Tatsuya
    Kobayashi, Yukio
    Uchida, Toshiki
    Fukuhara, Suguru
    Oyama, Takashi
    Fukuzaki, Tomoharu
    Komatsu, Yasuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Samaniego, Felipe
    Fayad, Luis E.
    Hagemeister, Fredrick B.
    McLaughlin, Peter
    Rodriguez, Maria Alma
    Weaver, Pam
    Hartig, Kim
    Badillo, Maria
    Kwak, Larry W.
    Younes, Anas
    Pro, Barbara
    Wang, Michael
    BLOOD, 2013, 122 (21)
  • [45] SINGLE-AGENT LENALIDOMIDE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A COMBINED ANALYSIS FROM THE MCL-001, NHL-002, AND NHL-003 STUDIES
    Witzig, T.
    Vose, J.
    Zinzani, P.
    Habermann, T.
    Tuscano, J.
    Sinha, R.
    Williams, M.
    Drach, J.
    Ramchandren, R.
    Besisik, S.
    Zhang, L.
    Cicero, S.
    Fu, T.
    Goy, A.
    HAEMATOLOGICA, 2013, 98 : 130 - 131
  • [46] Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    Robinson, K. Sue
    Williams, Michael E.
    van der Jagt, Richard H.
    Cohen, Philip
    Herst, Jordan A.
    Tulpule, Anil
    Schwartzberg, Lee S.
    Lemieux, Bernard
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4473 - 4479
  • [47] Lack of effect of bendamustine on Fridericia corrected QT interval (QTcF) in a phase III study of bendamustine-rituximab in advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).
    Burke, John M.
    Flinn, Ian
    Craig, Michael
    Van der Jagt, Richard H. C.
    MacDonald, David
    Hallman, Doreen M.
    Munteanu, Mihaela C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] PHASE I/II STUDY OF VELCADE®-BEAM (V-BEAM) AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA (NHL), TRANSFORMED OR MANTLE CELL LYMPHOMA (MCL)
    William, B. M.
    Allen, M. S.
    Loberiza, F. R.
    Bociek, R. G.
    Bierman, P. J.
    Aimitage, J. O.
    Vose, J. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S246 - S247
  • [50] Mantle cell lymphoma (MCL): Presenting failures and prognostic factors in a series of 59 patients.
    Bosch, F
    LopezGuillermo, A
    Campo, E
    Piris, MA
    Conde, E
    Ribera, JM
    Vallespi, T
    Woessner, S
    Montserrat, E
    BLOOD, 1996, 88 (10) : 889 - 889
12345